Genmab AS Financial Flexibility Index
Genmab AS financial flexibility index. Genmab AS (GMAB) has a Financial Flexibility Index of 0.04x as of December 2025. Free cash flow of $313.32 Million (operating CF $300.34 Million minus capex $12.99 Million) represents 0% of total liabilities ($7.01 Billion). Explore capital reinvestment ratio of Genmab AS to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Genmab AS (2002–2025)
Financial flexibility index of Genmab AS from 2002 to 2025. Historical Financial Flexibility Index trend for Genmab AS across 24 annual periods. Check Genmab AS (GMAB) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Genmab AS Financial Flexibility Index by Year (2002–2025)
Genmab AS financial flexibility index by year from 2002 to 2025. Year-by-year free cash flow to debt coverage for Genmab AS. For the full cash flow conversion analysis, see cash flow conversion of Genmab AS.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.17x | $1.22 Billion | $1.19 Billion | $7.01 Billion | ▼ -80.0% |
| 2024 | 0.87x | $7.96 Billion | $7.77 Billion | $9.11 Billion | ▼ -58.6% |
| 2023 | 2.11x | $7.76 Billion | $7.38 Billion | $3.68 Billion | ▲ +41.4% |
| 2022 | 1.49x | $4.23 Billion | $3.91 Billion | $2.84 Billion | ▲ +46.1% |
| 2021 | 1.02x | $2.48 Billion | $2.23 Billion | $2.43 Billion | ▼ -69.4% |
| 2020 | 3.33x | $6.74 Billion | $6.43 Billion | $2.02 Billion | ▲ +154.2% |
| 2019 | 1.31x | $1.44 Billion | $1.33 Billion | $1.10 Billion | ▼ -60.8% |
| 2018 | 3.34x | $1.49 Billion | $1.01 Billion | $446.64 Million | ▼ -34.1% |
| 2017 | 5.07x | $1.68 Billion | $1.59 Billion | $330.75 Million | ▲ +478.5% |
| 2016 | 0.88x | $360.83 Million | $327.72 Million | $411.54 Million | ▼ -18.4% |
| 2015 | 1.07x | $446.84 Million | $311.45 Million | $415.83 Million | ▲ +330.5% |
| 2014 | 0.25x | $208.11 Million | $132.67 Million | $833.74 Million | ▲ +327.5% |
| 2013 | -0.11x | $-117.63 Million | $-128.00 Million | $1.07 Billion | ▼ -279.8% |
| 2012 | 0.06x | $79.92 Million | $70.92 Million | $1.31 Billion | ▲ +115.3% |
| 2011 | -0.40x | $-430.02 Million | $-437.23 Million | $1.08 Billion | ▼ -300.9% |
| 2010 | 0.20x | $278.28 Million | $268.17 Million | $1.40 Billion | ▲ +133.2% |
| 2009 | -0.60x | $-553.28 Million | $-570.06 Million | $924.34 Million | ▼ -39.2% |
| 2008 | -0.43x | $-460.32 Million | $-513.33 Million | $1.07 Billion | ▼ -189.2% |
| 2007 | 0.48x | $518.74 Million | $505.90 Million | $1.08 Billion | ▲ +125.2% |
| 2006 | -1.92x | $-377.68 Million | $-379.62 Million | $197.05 Million | ▼ -133.9% |
| 2005 | -0.82x | $-206.21 Million | $-208.64 Million | $251.66 Million | ▲ +79.3% |
| 2004 | -3.95x | $-359.43 Million | $-367.70 Million | $90.92 Million | ▼ -28.7% |
| 2003 | -3.07x | $-287.66 Million | $-302.36 Million | $93.67 Million | ▼ -172.3% |
| 2002 | -1.13x | $-207.50 Million | $-308.32 Million | $183.97 Million | — |